Results 21 to 30 of about 1,392 (217)
Actinium-225 production with an electron accelerator [PDF]
Journal of Applied Physics, 2021 There has been growing clinical evidence of the value of targeted alpha therapy for the treatment of several cancers. The work has been slowed by the lack of availability of the key alpha emitting isotopes, especially Ac-225. It can be produced by photonuclear reaction, Ra-226(γ,n)Ra-225.
Diamond, W. T., Ross, C. K.
openaire +3 more sources
PLoS ONE, 2022 Hepatocellular carcinoma is the most common primary liver cancer and the fifth most frequently diagnosed cancer worldwide. Most patients with advanced disease are offered non-surgical palliative treatment options.
Yong Du +6 more
doaj +2 more sources
Actinium-225 targeted alpha particle therapy for prostate cancer. [PDF]
TheranosticsTargeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (225Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases sustained antitumor responses.
Bidkar AP +4 more
europepmc +5 more sources
EJNMMI Radiopharmacy and Chemistry, 2022 Background Quantification of actinium-225 through gamma counter measurements, when there is no secular equilibrium between actinium-225 and its gamma emitting daughters bismuth-213 and/or francium-221, can provide valuable information regarding the ...
Dayana Castillo Seoane +6 more
doaj +1 more source
Pharmaceuticals, 2022 In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 (225Ac) or the β--emitter lutetium-177 (177Lu) in mice.
Robin I. J. Merkx +11 more
doaj +1 more source
A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals
EJNMMI Radiopharmacy and Chemistry, 2021 Background As 225Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures.
James M. Kelly +5 more
doaj +1 more source
Actinium-225 in Targeted Alpha-Particle Therapeutic Applications [PDF]
Current Radiopharmaceuticalse, 2011 Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous ...
David A, Scheinberg, Michael R, McDevitt
openaire +2 more sources
H<sub>2</sub>BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy. [PDF]
Bioconjug Chem, 2022 Actinium-225 (225Ac) is one of the most promising radionuclides for targeted alpha therapy (TAT). With a half-life of 9.92 days and a decay chain that emits four high-energy α particles, 225Ac is well-suited for TAT when conjugated to macromolecular targeting vectors that exhibit extended in vivo circulation times.
Kadassery KJ +6 more
europepmc +5 more sources
EJNMMI Radiopharmacy and Chemistry, 2023 Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy which may benefit from radioimmunotherapy. Previously, [177Lu]Lu-DOTA-C595 has been developed as a beta-emitting radioimmunoconjugate to target cancer-specific mucin 1 ...
Ashleigh Hull +5 more
doaj +1 more source
Ac-EAZY! Towards GMP-Compliant Module Syntheses of 225Ac-Labeled Peptides for Clinical Application
Pharmaceuticals, 2021 The application of 225Ac (half-life T1/2 = 9.92 d) dramatically reduces the activity used for peptide receptor radionuclide therapy by a factor of 1000 in comparison to 90Y, 177Lu or 188Re while maintaining the therapeutic outcome.
Marc Pretze +8 more
doaj +1 more source